It was a good day for Argenx SE (ARGX) on Thursday. The biotech company delivered a one-two punch of positive news: promising late-stage clinical trial results for its flagship drug in a new disease area, and a quarterly earnings report that handily beat expectations.

First, the science. Argenx announced positive topline results from a Phase 3 study called ADAPT OCULUS. The trial was evaluating its drug, Vyvgart, in adults with ocular myasthenia gravis (oMG). If you're not familiar, that's an autoimmune disorder where the body's own antibodies mess up communication between nerves and muscles. The result is weak, easily tired eye muscles, which leads to two main problems: drooping eyelids (ptosis) and double vision (diplopia). It's as unpleasant as it sounds.

The study hit its primary goal, showing a "statistically significant improvement in patient-reported outcomes." In plain English, patients felt better. The numbers backed that up: patients on Vyvgart saw a mean improvement of 4.04 points on a specific disease score, compared to just a 1.99 point improvement for those on a placebo. The p-value was 0.012, which is science-speak for "this result is very unlikely to be a fluke."

This trial is a big deal because it's reportedly the first of its kind designed specifically to get a targeted therapy approved for this ocular form of the disease. The company said the safety profile looked consistent with what's been seen before, with no new red flags. The data is strong enough that Argenx plans to submit a Supplemental Biologics License Application to the FDA to get Vyvgart's official label expanded to cover oMG.

Now, the money. While the scientists were celebrating the trial data, the finance team was popping champagne over the quarterly results. Argenx reported fourth-quarter earnings of $8.02 per share. The consensus estimate was $6.02, so they beat it by a solid $2.00. Sales were even more impressive, jumping from $761.2 million in the prior year to $1.32 billion. That's a surge of over 70%, and it also beat the analyst consensus of $1.29 billion.

"Argenx delivered another standout year of execution in 2025," said CEO Tim Van Hauwermeiren. He highlighted that the company reached 19,000 patients globally with Vyvgart and made progress across its development pipeline.

Analysts liked what they saw. William Blair wrote that they believe the new oMG data "will continue to solidify Vyvgart as the preferred biologic therapy across all MG patients and continue to increase first-line biologic market share."

So, what does all this mean for the stock? Let's look at the technical picture. The stock is trading well above its 200-day simple moving average, which suggests strong long-term momentum is intact. Over the past year, shares have trended higher and are closer to their 52-week highs than their lows.

The shorter-term signals, however, are a bit mixed. The Relative Strength Index (RSI) is sitting right at 50.00, which is considered neutral territory—the stock isn't overbought or oversold. But the Moving Average Convergence Divergence (MACD) indicator is at 0.15, which is below its signal line of 0.22. That hints at some bearish pressure in the very near term. Traders often watch for a potential shift when indicators conflict like this.

For those watching key levels, analysts note a key resistance point at $850.00 and key support at $750.00. On Thursday, the stock was down slightly in premarket trading, with shares of Argenx at $808.02.